Clinical Trials Logo
  1. Home
  2. HER2-positive Gastric Cancer
  3. NCT05715931

Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

HER2-positive Gastric Cancer Clinical Trial

Official title:
A Multi-center, Phase II Study to Evaluate Efficacy and Safety of Perioperative Chemotherapy With Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel (FLOT) and Trastuzumab in Combination With Toripalimab in Patients With HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Clinical Trial Summary

This study is a prospective, single arm, multi-center phase II clinical trial designed to evaluate the efficacy and safety of perioperative chemotherapy with FLOT regimen and trastuzumab in combination with toripalimab in participants with resectable HER2 positive locally advanced gastric or esophagogastric junction adenocarcinoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05715931
Study type Interventional
Source First Affiliated Hospital of Zhejiang University
Contact Jiren Yu
Phone 0086-0571-87237931
Email yujr0909@zju.edu.cn
Status Recruiting
Phase Phase 2
Start date February 28, 2023
Completion date March 1, 2028
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05070598 - Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer Phase 2
Active, not recruiting NCT04082364 - Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Phase 2/Phase 3
Completed NCT03330561 - PRS-343 in HER2-Positive Solid Tumors Phase 1
Recruiting NCT05619016 - [68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors Phase 2
Not yet recruiting NCT05586061 - First-line Treatment With RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer Phase 2
Active, not recruiting NCT05190445 - Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma Phase 2
Recruiting NCT05982834 - Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC Phase 1/Phase 2
Not yet recruiting NCT05313906 - RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer Phase 2
Recruiting NCT06328738 - ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer Phase 1
Recruiting NCT04319757 - ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors Phase 1
Recruiting NCT04520295 - ctDNA Screening in Advanced HER2 Positive Gastric Cancer
Withdrawn NCT04464967 - Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers Phase 1/Phase 2
Recruiting NCT06253650 - Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease Phase 2
Recruiting NCT05955833 - 89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study Phase 1
Not yet recruiting NCT06414733 - Vaccine Therapy in Treating Patients With Metastatic Solid Tumors Phase 1
Active, not recruiting NCT05555251 - BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors Phase 1/Phase 2
Withdrawn NCT04602117 - ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer Phase 1
Not yet recruiting NCT06439550 - Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC Phase 2
Recruiting NCT05514717 - A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 Phase 1
Terminated NCT05091528 - A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers Phase 1/Phase 2